197 related articles for article (PubMed ID: 15627717)
1. Comparison of effects of different heparins on thrombin activatable fibrinolysis inhibitor in hemodialyzed patients.
Małyszko J; Małyszko JS; Hryszko T; Pawlak K; Myśliwiec M
Am J Nephrol; 2004; 24(6):624-9. PubMed ID: 15627717
[TBL] [Abstract][Full Text] [Related]
2. Thrombin activatable fibrinolysis inhibitor (TAFI) and markers of endothelial cell injury in dialyzed patients with diabetic nephropathy.
Małyszko J; Małyszko JS; Hryszko T; Myśliwiec M
Thromb Haemost; 2004 Mar; 91(3):480-6. PubMed ID: 14983223
[TBL] [Abstract][Full Text] [Related]
3. Different effects of enoxaparin and unfractionated heparin on some thrombogenesis markers during hemodialysis: a cross-over study.
Naumnik B; Pawlak K; Myśliwiec M
Thromb Res; 2009 Feb; 123(4):631-6. PubMed ID: 18234290
[TBL] [Abstract][Full Text] [Related]
4. Age-based difference in activation markers of coagulation and fibrinolysis in extracorporeal membrane oxygenation.
Hundalani SG; Nguyen KT; Soundar E; Kostousov V; Bomgaars L; Moise A; Hui SK; Teruya J
Pediatr Crit Care Med; 2014 Jun; 15(5):e198-205. PubMed ID: 24614609
[TBL] [Abstract][Full Text] [Related]
5. Coagulation-fibrinolysis changes during off-pump bypass: effect of two heparin doses.
Paparella D; Semeraro F; Scrascia G; Galeone A; Ammollo CT; Kounakis G; de Luca Tupputi Schinosa L; Semeraro N; Colucci M
Ann Thorac Surg; 2010 Feb; 89(2):421-7. PubMed ID: 20103314
[TBL] [Abstract][Full Text] [Related]
6. Thrombin activatable fibrinolysis inhibitor in hypertensive kidney transplant recipients.
Malyszko J; Malyszko JS; Hryszko T; Mysliwiec M
Transplant Proc; 2006; 38(1):105-7. PubMed ID: 16504676
[TBL] [Abstract][Full Text] [Related]
7. Different effects of enoxaparin, nadroparin, and dalteparin on plasma TFPI during hemodialysis: a prospective crossover randomized study.
Naumnik B; Rydzewska-Rosołowska A; Myśliwiec M
Clin Appl Thromb Hemost; 2011 Oct; 17(5):480-6. PubMed ID: 20682597
[TBL] [Abstract][Full Text] [Related]
8. Unfractionated heparin but not enoxaparin causes delayed plasma PAI-1 depletion in hemodialysis patients: a prospective study.
Naumnik B; Pawlak K; Mys'liwiec M
Clin Appl Thromb Hemost; 2009 Feb; 15(1):84-91. PubMed ID: 17895513
[TBL] [Abstract][Full Text] [Related]
9. Fluvastin therapy affects TAFI concentration in kidney transplant recipients.
Malyszko J; Malyszko JS; Mysliwiec M
Transpl Int; 2003 Jan; 16(1):53-7. PubMed ID: 12545342
[TBL] [Abstract][Full Text] [Related]
10. Comparison of enoxaparin and unfractionated heparin on thrombin generation in acute coronary syndromes without ST-segment elevation.
Salvioni A; Casilli F; Assanelli E; Grazi M; Marenzi G; Guazzi MD
Thromb Haemost; 2001 Oct; 86(4):991-4. PubMed ID: 11686357
[TBL] [Abstract][Full Text] [Related]
11. Structural changes in carotid arteries and impairment of fibrinolysis in hemodialyzed and peritoneally dialyzed patients.
Małyszko J; Łebkowska U; Małyszko JS; Myśliwiec M
Med Sci Monit; 2009 Dec; 15(12):CR644-9. PubMed ID: 19946236
[TBL] [Abstract][Full Text] [Related]
12. Safety and efficacy of single bolus anticoagulation with enoxaparin for chronic hemodialysis. Results of an open-label post-certification study.
Klingel R; Schwarting A; Lotz J; Eckert M; Hohmann V; Hafner G
Kidney Blood Press Res; 2004; 27(4):211-7. PubMed ID: 15273423
[TBL] [Abstract][Full Text] [Related]
13. [Thrombin activatable fibrinolysis o inhibitor-TAFI- in dialyzed patients with diabetic nephropathy].
Małyszko JS; Małyszko J; Hryszko T; Myśliwiec M
Pol Arch Med Wewn; 2003 Aug; 110(2):843-8. PubMed ID: 14682222
[TBL] [Abstract][Full Text] [Related]
14. [Thrombin activatable fibrinolysis inhibitor (TAFI) in allergic asthma patients].
Kemona-Chetnik I; Kowal K; Kucharewicz I; Pampuch A; Bodzenta-Lukaszyk A
Przegl Lek; 2006; 63(12):1281-5. PubMed ID: 17642140
[TBL] [Abstract][Full Text] [Related]
15. The role of protein S in the activation of thrombin activatable fibrinolysis inhibitor (TAFI) and regulation of fibrinolysis.
Mosnier LO; Meijers JC; Bouma BN
Thromb Haemost; 2001 Oct; 86(4):1040-6. PubMed ID: 11686322
[TBL] [Abstract][Full Text] [Related]
16. Differential regulation of thrombin activatable fibrinolytic inhibitor by low molecular weight heparins. Pharmacologic implications.
Florian-Kujawski M; Hoppensteadt D; Maddineni J; Ziegler H; Fareed J
Int Angiol; 2004 Dec; 23(4):346-54. PubMed ID: 15767980
[TBL] [Abstract][Full Text] [Related]
17. A comprehensive study on hemostasis in CAPD patients treated with erythropoietin.
Malyszko J; Suchowierska E; Malyszko JS; Mysliwiec M
Perit Dial Int; 2002; 22(5):582-92. PubMed ID: 12455569
[TBL] [Abstract][Full Text] [Related]
18. Some aspects of hemostasis in CAPD patients treated with erythropoietin.
Małyszko J; Suchowierska E; Małyszko JS; Myśliwiec M
Kidney Blood Press Res; 2002; 25(4):240-4. PubMed ID: 12424426
[TBL] [Abstract][Full Text] [Related]
19. Thromboprophylaxis following caesarean section--a comparison of the antithrombotic properties of three low molecular weight heparins--dalteparin, enoxaparin and tinzaparin.
Ellison J; Thomson AJ; Conkie JA; McCall F; Walker D; Greer A
Thromb Haemost; 2001 Dec; 86(6):1374-8. PubMed ID: 11776302
[TBL] [Abstract][Full Text] [Related]
20. Effects of heparin and dalteparin on oxidative stress during hemodialysis in patients with end-stage renal disease.
Nassiri AA; Hakemi MS; Soulati M; Marashian M; Rahbar K; Azizi F
Iran J Kidney Dis; 2009 Jul; 3(3):162-7. PubMed ID: 19617666
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]